Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of cleadewGP for Rigid Contact Lenses

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03193255
Recruitment Status : Active, not recruiting
First Posted : June 20, 2017
Last Update Posted : February 22, 2019
Sponsor:
Collaborator:
OPHTECS Corporation
Information provided by (Responsible Party):
Pauline Cho, The Hong Kong Polytechnic University

Brief Summary:
Multipurpose solutions (MPS) are the most commonly prescribed regimen to clean, disinfect and rinse rigid lenses. The preservatives used in MPS may cause hypersensitivity and the presence of quaternary ammonium compounds (QAC) may increase development of antiseptic resistance mediated by QAC resistance genes, thus lowering the efficacy of disinfection. Povidone-iodine (PVI) has been safely used as a disinfectant for ophthalmic operations and eye drops. The cleadew GP (Ophtecs, Japan) tested in the current study is a PVI based rigid lens disinfecting solutions which does not employ QAC. If its efficacy and safety can be confirmed in this study, it will be a good alternative rigid lens care regimen for children.

Condition or disease Intervention/treatment Phase
Contact Lens Solution Toxicity Device: OPHTECS cleadew GP Not Applicable

Detailed Description:

Multipurpose solutions (MPS) are the most commonly prescribed regimen to clean, disinfect and rinse rigid lenses. These solutions usually contain quaternary ammonium compounds (QAC) which have been shown to be selective for carriage of organisms harbouring QAC genes in orthokeratology (ortho-k) lens wear and it raises concerns about safety with the increasing popularity of orthokeratology (ortho-k) for myopia control in children. Hydrogen peroxide system is a good alternative but this option is limited in rigid lens market. The only brand available in Hong Kong labelled as safe for rigid contact lenses has limited disinfecting power. cleadewGP (Ophtecs, Japan) is a new disinfecting solution for rigid contact lenses which does not employ QAC and instead is povidone iodine (PVI) based. PVI has been safely used as a disinfectant for ophthalmic operations and is commonly used in eye drops. PVI-based soft and rigid lens solutions have been reported to be as effective against Pseudomonas aeruginosa as other MPS and hydrogen peroxide-based solutions. However, other efficacy against other organisms need to be demonstrated to allow this solution to meet FDA requirements. The PVI-based soft lens solution was also reported to be effective against Acanthamoeba. cleadewGP is relatively new in the market and not much work has been done on the efficacy and safety of this solution. If confirmed to be effective and safe, cleadewGP may be a better alternative to ortho-k lens wearers who need to use disinfecting solutions at least for a few years while under ortho-k treatment. In the absence of QAC, there will be no concern of selection of carriage of organisms harbouring QAC genes in ortho-k lens wearers using this disinfecting solution over time.

The current study aims at investigating the effectiveness and safety of the cleadewGP for cleaning (lipid and protein removal) and disinfecting of ortho-k lenses by comparing the outcomes collected from subjects randomly assigned to one of the following study groups.

Group 1: cleadewGP without lens rubbing Group 2: cleadewGP with lens rubbing Group 3: cleadewGP with separate daily cleaner Group 4: cleadewGP with separate daily cleaner and weekly protein removal agent

Four study visits will be involved in this 6 months study: baseline, 1-month, 3-month, and 6-month after lens wear. Complimentary solutions will be provided during the study period. Solutions and accessories will be replaced at monthly interval. Effectiveness for cleaning and disinfection and safety of lens wear will be determined by comparing the changes in ocular microbiome before and after lens wear, contamination levels of lenses and accessories, biomicroscopic examination of lenses and eyes, and subjective rating of lens comfort among the four groups of subjects.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Povidone Iodine-based Disinfecting Solution (cleadewGP) for Rigid Contact Lenses
Actual Study Start Date : June 14, 2017
Estimated Primary Completion Date : June 30, 2019
Estimated Study Completion Date : August 31, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eye Wear

Arm Intervention/treatment
Active Comparator: No daily lens rubbing
Daily lens disinfection with OPHTECS cleadew GP without lens rubbing
Device: OPHTECS cleadew GP
Povidone-iodine based disinfecting solutions for rigid contact lenses

Active Comparator: Daily rubbing
Daily lens disinfection with OPHTECS cleadew GP after lens rubbing with cleadew GP
Device: OPHTECS cleadew GP
Povidone-iodine based disinfecting solutions for rigid contact lenses

Active Comparator: Daily rubbing with separate cleaner
Daily lens disinfection with OPHTECS cleadew GP after lens rubbing with a daily lipid cleaner
Device: OPHTECS cleadew GP
Povidone-iodine based disinfecting solutions for rigid contact lenses

Active Comparator: Daily rubbing and weekly protein removal
Daily lens disinfection with OPHTECS cleadew GP after daily lipid cleaner followed by weekly protein removal treatment
Device: OPHTECS cleadew GP
Povidone-iodine based disinfecting solutions for rigid contact lenses




Primary Outcome Measures :
  1. Change in subjective symptoms before and 6 months after lens wear [ Time Frame: 6 months ]
    Questionnaire of ocular comfort will be administered to rate symptoms of discomfort, itching, tearing, dryness and redness

  2. Change in corneal staining and injection before and 6 months after ortho-k lens wear [ Time Frame: 6 months ]
    Grading of corneal staining, limbal injection and conjunctival injection under slitlamp biomicroscopy before and after ortho-k lens wear


Secondary Outcome Measures :
  1. Change in levels of ocular microbiome before and 6 months after ortho-k lens wear [ Time Frame: 6 months ]
    Sample from the lower conjunctiva will be gently taken with cotton swab pre-wet with normal saline before and ortho-k lens wear

  2. Levels of contamination of lens cases [ Time Frame: 6 months ]
    Sample will be collected from the left compartment of the lens case to determine the presence of microorganisms. The right compartment of the lens case will be tested for the presence and amount of biofilm

  3. Levels of contamination of lenses [ Time Frame: 6 months ]
    Samples will be collected from the left lens surface to test for the presence of microorganisms



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 10 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • cycloplegic objective sphere between -1.00D to -4.00D
  • cycloplegic objective astigmatism ≤ 2.00D
  • anisometropia < 1.00D
  • best-corrected logMAR visual acuity 0.10 or better in both eyes
  • symmetrical corneal topography with toricity ≤ 2.00D
  • normal ocular health

Exclusion Criteria:

  • contraindication to ortho-k wear
  • prior history of myopia control treatment
  • prior history of rigid contact lens wear
  • strabismus or amblyopia
  • systemic or ocular conditions which might affect refractive development
  • poor response or poor compliance to lens wear including poor lens handling, poor vision, and/ocular response after lens modifications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03193255


Locations
Layout table for location information
Hong Kong
School of Optometry, The Hong Kong Polytechnic University
Kowloon, Hong Kong
Sponsors and Collaborators
The Hong Kong Polytechnic University
OPHTECS Corporation
Investigators
Layout table for investigator information
Principal Investigator: Pauline Cho, PhD The Hong Kong Polytechnic University

Publications:
Layout table for additonal information
Responsible Party: Pauline Cho, Professor, The Hong Kong Polytechnic University
ClinicalTrials.gov Identifier: NCT03193255     History of Changes
Other Study ID Numbers: HSEARS20170430002
First Posted: June 20, 2017    Key Record Dates
Last Update Posted: February 22, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Povidone
Povidone-Iodine
Plasma Substitutes
Blood Substitutes
Anti-Infective Agents, Local
Anti-Infective Agents